Emerging therapeutic modalities for diabetic retinopathy

Abstract

Diabetic retinopathy and diabetic macular edema (DR/DME) are among the leading causes of irreversible vision loss in the working age population. Emerging therapeutic modalities are being engineered to improve clinical management of DR/DME with improved clinical outcomes. This is evidenced by prolongation of therapeutic half-life to reduce treatment burdens, multi-targeted therapies which address multiple disease mediators, and innovative methods to improve tissue penetration and cell selectivity. We report here on selected novel ocular drug delivery technologies and therapeutic modalities, and their potential as game-changing clinical approaches for addressing the sight-threatening complications of diabetes.